AGuIX gadolinium-based nanoparticles

Phase 2Small molecule

AGuIX gadolinium-based nanoparticles is one of 27 small molecule programs targeting Brain Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain CancerRecruiting

Brain CancerPhase 2

Recruiting

Competition

Competitive Landscape

26 competitors in Brain Cancer

#DrugCompanyPhaseTrials

Jevtana

Actos

Opdivo

4 4

Tarceva

OOSI Pharmaceuticals

Approved

—5

Decadron

AAspen Global Incorporated

Approved

—6

Photofrin

PPinnacle Biologics Inc.

Aloxi

Glucophage

Trisenox

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Brain Cancer

NCT04899908

Clinical

Trials by Indication[1]

Brain Cancer1 trial

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT04899908·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AGuIX gadolinium-based nanoparticles. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGuIX gadolinium-based nanoparticles compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGuIX gadolinium-based nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brigham and Women's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBrigham and Women's Hospital

AGuIX gadolinium-based nanoparticles

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Brain Cancer1 trial

References

Drug Info

Quick Facts

Related News